Hemorrhagic Fever News and Research

RSS

Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).

5 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Scientists block Ebola infection in cell-culture experiments - could lead to first therapy

Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.

23 Jun 2009

Ghana launches public-private partnership to control malaria

Ghana's Ministry of Health recently launched the Nationwide Mosquito Control Programme (NAMCOP) in conjunction with the waste management company Zoomlion Ghana Limited, the Ghanaian Chronicle/allAfrica.com reports (Akweetey, Ghanaian Chronicle/allAfrica.com, 6/19).

22 Jun 2009

Scientists use climate variables and vegetation indices to predict and mitigate Dengue epidemics

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are the most important vector-borne viral diseases in the World. Around 50-100 million cases appear each year putting 2.5 billion people at risk of suffering this debilitating and sometimes fatal disease.

5 Jun 2009

Discovery of new arenavirus associated with hemorrhagic fever – first identified in nearly four decades

Scientists at Columbia University's Mailman School of Public Health, the South African National Institute for Communicable Diseases of National Health Laboratory Service (NICD-NHLS), the U.S. Centers for Disease Control and Prevention, and Roche's 454 Life Sciences Corporation have discovered the new virus responsible for a highly fatal hemorrhagic fever outbreak in Zambia and South Africa in late 2008.

2 Jun 2009

New research nets the true economic costs of dengue fever

Researchers at Brandeis, in collaboration with several other institutions worldwide, have pinpointed for the first time the multi-country economic costs of dengue fever, the endemic and epidemic mosquito-borne illness that is a rapidly growing public health problem in tropical and sub-tropical countries.

7 May 2009

European viral epidemic linked to global warming

An epidemic of the viral disease nephropathia epidemica (NE) has been linked to increases in the vole population caused by hotter summers, milder winters and increased seedcrop production by broadleaf trees.

19 Jan 2009

Researchers solve structure of key Ebola protein

Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus.

12 Jan 2009

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Discovery of new species of Ebola virus

Scientists report the discovery of a new species of Ebola virus, provisionally named Bundibugyo ebolavirus, November 21 in the open-access journal PLoS Pathogens.

20 Nov 2008

Researchers look at spread of dengue virus in rural Thai villages

In a new study reported in PLoS Medicine, Mammen P. Mammen Jr. of the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok and colleagues investigated the spread of dengue virus infection in rural Thai villages.

4 Nov 2008

Scientists find structure of critical Ebola virus protein

Scientists at the Scripps Research Institute have uncovered the structure of a critical protein from the Ebola Virus that allows viral entry in human cells.

23 Jul 2008

Breakthrough findings point to targets for Ebola virus drugs and vaccines

Described in the July 10, 2008 issue of the journal Nature, the research reveals the shape of the Ebola virus spike protein, which is necessary for viral entry into human cells, bound to an immune system antibody acting to neutralize the virus. The structure provides a major step forward in understanding how the deadly virus works, and may be useful in the development of potential Ebola virus vaccines, or treatments for those infected.

10 Jul 2008

Chapare virus, a newly discovered arenavirus

A team of Bolivian health authorities, U.S. Navy health experts based in Lima, Peru, and the U.S. Centers for Disease Control and Prevention has characterized "Chapare arenavirus," a previously unrecognized arenavirus, discovered in serum samples from a patient in rural Bolivia who eventually died of the infection.

17 Apr 2008